Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on February 27, 2018, with the earliest event reported on that date. The filing primarily addresses executive leadership changes, specifically the upcoming retirement of a senior officer and the appointment of a new President and Chief Operating Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements rather than financial performance metrics.
Material Changes
- Executive Departure: Kathryn L. Biberstein, Executive Vice President, Chief Compliance Officer, Chief Administrative Officer, and Chief Risk Officer, will retire effective June 30, 2018. Her responsibilities will transition to other executive management members beginning March 5, 2018.
- Executive Appointment: James Robinson was appointed President and Chief Operating Officer, effective March 5, 2018. Prior to joining Alkermes, Mr. Robinson served as President, Americas Operations for Astellas US LLC.
Compensatory Arrangements and Outlook
Mr. Robinson's employment agreement includes the following financial terms:
- Base Salary: $675,000 annually.
- Sign-on Bonus: $1,000,000.
- Annual Target Bonus: 75% of base salary, contingent on individual and company performance objectives.
- Equity Awards: An option to purchase 140,000 ordinary shares and a restricted stock unit award of 25,000 ordinary shares, both vesting ratably over four years.
- Severance Provisions:
- Standard Termination: If terminated without Cause or for Good Reason, Mr. Robinson receives one times the sum of his base salary plus the average annual bonus of the prior two years, paid over 12 months, plus 12 months of health benefits.
- Change in Control: If terminated within 24 months of a Change in Control, he receives a pro-rata bonus plus a lump sum equal to two times the sum of his base salary plus the average annual bonus of the prior two years, plus 18 months of health benefits.
The filing does not contain specific guidance, risk factors, or contingencies beyond the standard restrictive covenants and indemnification agreements associated with the new executive appointment.
Investor Verification Checklist
- Verify the transition plan for Kathryn L. Biberstein's responsibilities starting March 5, 2018.
- Confirm the vesting schedule and exercise price for Mr. Robinson's equity awards once granted.
- Review the specific performance objectives for Mr. Robinson's annual bonus as determined by the Compensation Committee.
- Monitor the press release dated March 1, 2018 (Exhibit 99.1) for additional public commentary on the leadership changes.